HRP20080052T3 - Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation - Google Patents

Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation

Info

Publication number: HRP20080052T3
Authority: HR; Croatia
Prior art keywords: hiv; inflammation; treatment; receptor antagonist; antagonist activity
Prior art date: 2003-10-03

Application number

HR20080052T

Other languages

English (en)

Croatian (hr)

Inventor

Anthony Stupple Paul

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-03

Filing date

2008-01-30

Publication date

2008-02-29

2003-10-03 Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en

2003-10-27 Priority claimed from GB0325020A external-priority patent/GB0325020D0/en

2004-08-19 Priority claimed from GB0418566A external-priority patent/GB0418566D0/en

2008-01-30 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2008-02-29 Publication of HRP20080052T3 publication Critical patent/HRP20080052T3/xx

Links

206010061218 Inflammation Diseases 0.000 title 1
239000003067 chemokine receptor CCR5 antagonist Substances 0.000 title 1
125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
150000003813 tropane derivatives Chemical class 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

HR20080052T 2003-10-03 2008-01-30 Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation HRP20080052T3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0323236.0A GB0323236D0 (en)	2003-10-03	2003-10-03	Chemical compounds
GB0325020A GB0325020D0 (en)	2003-10-27	2003-10-27	Chemical compounds
GB0418566A GB0418566D0 (en)	2004-08-19	2004-08-19	Tropane derivatives
PCT/IB2004/003153 WO2005033107A1 (fr)	2003-10-03	2004-09-28	Derives de tropane a substitution imidazopyridine en tant qu'antagonistes des recepteurs ccr5 pour le traitement du vih et de l'inflammation

Publications (1)

Publication Number	Publication Date
HRP20080052T3 true HRP20080052T3 (en)	2008-02-29

Family

ID=34426592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20080052T HRP20080052T3 (en)	2003-10-03	2008-01-30	Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation

Country Status (35)

Country	Link
US (2)	US7309790B2 (fr)
EP (1)	EP1682545B1 (fr)
JP (1)	JP4874107B2 (fr)
KR (1)	KR100777885B1 (fr)
AP (1)	AP2174A (fr)
AR (1)	AR045856A1 (fr)
AT (1)	ATE380813T1 (fr)
AU (1)	AU2004278158B2 (fr)
BR (1)	BRPI0414862A (fr)
CA (1)	CA2540834C (fr)
CY (1)	CY1107281T1 (fr)
DE (1)	DE602004010708T2 (fr)
DK (1)	DK1682545T3 (fr)
EA (1)	EA009941B1 (fr)
EC (1)	ECSP066475A (fr)
ES (1)	ES2295924T3 (fr)
GE (1)	GEP20084417B (fr)
HN (1)	HN2004000383A (fr)
HR (1)	HRP20080052T3 (fr)
IL (1)	IL174208A0 (fr)
MA (1)	MA28080A1 (fr)
MX (1)	MXPA06003749A (fr)
MY (1)	MY137609A (fr)
NO (1)	NO20061978L (fr)
NZ (1)	NZ545837A (fr)
OA (1)	OA13266A (fr)
PA (1)	PA8614301A1 (fr)
PE (1)	PE20050961A1 (fr)
PL (1)	PL1682545T3 (fr)
PT (1)	PT1682545E (fr)
RS (1)	RS20060198A (fr)
SI (1)	SI1682545T1 (fr)
TW (1)	TWI280244B (fr)
UY (1)	UY28546A1 (fr)
WO (1)	WO2005033107A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
CN1849318B (zh)	2003-07-30	2011-10-12	里格尔药品股份有限公司	用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
KR101312225B1 (ko)	2005-06-08	2013-09-26	리겔 파마슈티칼스, 인크.	Ｊａｋ 경로의 억제를 위한 조성물 및 방법
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
WO2007114921A2 (fr)	2006-04-05	2007-10-11	Schering Corporation	Formulations pharmaceutiques : sels de 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one et méthodes de traitement utilisant lesdits sels
WO2008030853A2 (fr) *	2006-09-06	2008-03-13	Incyte Corporation	Thérapie de combinaison contre l'infection par le virus de l'immunodéficience humaine
DE602007012363D1 (de)	2006-10-19	2011-03-17	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
WO2008085302A1 (fr) *	2006-12-20	2008-07-17	Merck & Co., Inc.	Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
AR065802A1 (es) *	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
NZ585137A (en) *	2007-10-25	2012-07-27	Exelixis Inc	Tropane compounds useful as hsp90 inhibitors
PL2265607T3 (pl)	2008-02-15	2017-07-31	Rigel Pharmaceuticals, Inc.	Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
CA2723185A1 (fr)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibiteurs de proteines kinases
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
RU2017145628A (ru)	2009-08-14	2019-02-19	ОПКО Хельс, Инк.	Композиции антагонистов нейрокинина-1 для внутривенного введения
BR112012024522A2 (pt)	2010-04-02	2017-08-08	Phivco 1 Llc	combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
US9102625B2 (en)	2010-11-01	2015-08-11	Portola Pharmaceuticals, Inc.	Nicotinamides as JAK kinase modulators
US20140271680A1 (en)	2011-08-12	2014-09-18	Universite Paris-Est Creteil Val De Marne	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2782579B1 (fr)	2011-11-23	2019-01-02	Portola Pharmaceuticals, Inc.	Inhibiteurs de de la pyrazine kinase
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
PL3049378T3 (pl) *	2013-09-25	2019-06-28	SpecGx LLC	Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT
GB201321748D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
WO2023192360A1 (fr) *	2022-03-31	2023-10-05	Incelldx, Inc.	Méthodes de traitement d'un sujet pour une maladie de lyme post-traitement (ptld) et compositions destinées à être utilisées dans celles-ci
WO2023192361A1 (fr) *	2022-03-31	2023-10-05	Incelldx, Inc.	Procédés de traitement d'un sujet pour la fibromyalgie et compositions destinées à être utilisées dans ceux-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR100210417B1 (ko)	1994-04-19	1999-07-15	페더 벨링	신경전달물질 재흡수 억제제인 트로판-2-알독심 유도체
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
ATE203023T1 (de)	1996-02-22	2001-07-15	Neurosearch As	Tropanderivate, deren herstellung und verwendung
WO2000035298A1 (fr)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
PE20001420A1 (es) *	1998-12-23	2000-12-18	Pfizer	Moduladores de ccr5
TR200400541T4 (tr) *	2000-05-26	2004-04-21	Pfizer Inc.	Terapide faydalı tropan türevleri.
CN1324025C (zh) *	2002-04-08	2007-07-04	美国辉瑞有限公司	作为ccr5调节剂的托烷衍生物
US6855724B2 (en) *	2002-04-08	2005-02-15	Agouron Pharmaceuticals, Inc.	Tropane derivatives useful in therapy

2004
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 EP EP04769496A patent/EP1682545B1/fr active Active
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es active Active
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active IP Right Cessation
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de active Active
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/fr active IP Right Grant
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 CA CA2540834A patent/CA2540834C/fr not_active Expired - Fee Related
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
2008
- 2008-01-30 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown

Also Published As

Publication number	Publication date
KR100777885B1 (ko)	2007-11-28
EP1682545A1 (fr)	2006-07-26
MXPA06003749A (es)	2006-06-14
SI1682545T1 (sl)	2008-04-30
TW200519112A (en)	2005-06-16
TWI280244B (en)	2007-05-01
US20050131011A1 (en)	2005-06-16
US7309790B2 (en)	2007-12-18
US20080045563A1 (en)	2008-02-21
DE602004010708T2 (de)	2008-12-04
ES2295924T3 (es)	2008-04-16
DE602004010708D1 (de)	2008-01-24
PT1682545E (pt)	2008-02-11
KR20060070571A (ko)	2006-06-23
MA28080A1 (fr)	2006-08-01
CY1107281T1 (el)	2012-11-21
MY137609A (en)	2009-02-27
IL174208A0 (en)	2006-08-01
BRPI0414862A (pt)	2006-11-28
DK1682545T3 (da)	2008-03-17
WO2005033107A1 (fr)	2005-04-14
US7790740B2 (en)	2010-09-07
JP4874107B2 (ja)	2012-02-15
AU2004278158A1 (en)	2005-04-14
EA200600480A1 (ru)	2006-08-25
ATE380813T1 (de)	2007-12-15
AU2004278158B2 (en)	2009-08-13
OA13266A (en)	2007-01-31
AR045856A1 (es)	2005-11-16
EA009941B1 (ru)	2008-04-28
AP2006003580A0 (en)	2006-04-30
PL1682545T3 (pl)	2008-04-30
NO20061978L (no)	2006-07-03
CA2540834C (fr)	2010-06-22
AP2174A (en)	2010-11-20
PE20050961A1 (es)	2005-11-29
GEP20084417B (en)	2008-07-10
HN2004000383A (es)	2008-10-14
RS20060198A (en)	2008-09-29
EP1682545B1 (fr)	2007-12-12
UY28546A1 (es)	2005-05-31
CA2540834A1 (fr)	2005-04-14
ECSP066475A (es)	2006-10-10
JP2007507483A (ja)	2007-03-29
PA8614301A1 (es)	2005-05-10
NZ545837A (en)	2009-12-24

Publication	Publication Date	Title
HRP20080052T3 (en)	2008-02-29	Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
EP1939175A4 (fr)	2009-07-22	Dérivé sulfonamide ayant une activité antagoniste de récepteur pgd2
TW200744587A (en)	2007-12-16	Azaindole derivatives exhibiting PGD2 receptor antagonism
HRP20090162T1 (en)	2009-05-31	Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
DE60204674D1 (de)	2005-07-21	Retinoid x rezeptormodulatoren
HRP20020938B1 (en)	2011-05-31	Tropane derivatives useful in therapy
WO2005056554A3 (fr)	2005-08-18	Derives d'azepinoindole en tant qu'agents pharmaceutiques
DK1069124T3 (da)	2004-09-13	2-Benzimidazolylamin-forbindelser som ORL1-receptor-agonister
KR20050085991A (en)	2005-08-29	Compounds exhibiting thrombopoietin receptor agonism
ATE296821T1 (de)	2005-06-15	Triarylimidazol-derivate als cytokin-inhibitoren
BRPI0511504A (pt)	2008-01-22	composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
NO20074641L (no)	2007-11-01	1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
TW200734322A (en)	2007-09-16	Indole derivatives exhibiting PGD2 receptor antagonism
DK2041133T3 (da)	2011-02-07	Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
AR037682A1 (es)	2004-12-01	Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
TW200745101A (en)	2007-12-16	9-Azabicyclo[3.3.1]nonane derivatives
PT1261602E (pt)	2004-08-31	Derivados imidazol-2-carboxamida como inibidores de cinase raf
BRPI0707491B8 (pt)	2021-05-25	compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
NO20064297L (no)	2006-11-23	Aminoalkoholforbindelse
ATE302775T1 (de)	2005-09-15	Carbolinderivate
NO20064705L (no)	2006-12-19	Nye farmasoytiske preparater omfattende agonister av tyroidreseptoren
DE60317326D1 (de)	2007-12-20	Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
ATE346067T1 (de)	2006-12-15	Carbolinderivate
ATE386012T1 (de)	2008-03-15	Phenyloxyalkansäure-derivate als hppar aktivatore
SE0401655D0 (sv)	2004-06-24	New compounds